ACT reports Q1 2026 earnings today against a backdrop defined less by short sellers than by its majority owner steadily reducing its stake.
The dominant positioning signal is Genworth's ongoing selldown. Parent Genworth Holdings shed over 1.38 million shares in two tranches — roughly $57.4 million worth — across March and April alone. That follows a further $16.8 million disposal in late February. Over 90 days, net insider selling across all parties totals nearly $80 million in value. Genworth still controls approximately 79.9% of ACT's shares, so supply pressure from continued secondary sales is the structural overhang the market is pricing. The CEO sold $3.4 million of stock in February, adding a secondary signal of caution at the management level.
Options positioning reinforces the cautious tone, though not dramatically so. The put/call ratio has climbed to 0.22 — still low in absolute terms, but running nearly two standard deviations above its 20-day average of 0.09. That marks a meaningful shift in options market sentiment relative to recent weeks, when calls overwhelmingly dominated activity. Short interest, by contrast, is not a meaningful factor here. At 2.5% of the free float — up around 6.5% over the past month — it reflects only a modest short position, and borrow conditions remain unambiguous. Cost to borrow is just 0.50%, down sharply from its early-April peak near 0.86%, and availability in the lending market is wide open. There is no squeeze dynamic at play.
The analyst community is mildly constructive but not enthusiastic. B of A Securities lifted its target to $49 on April 21 while maintaining a Buy — the most recent bellwether move, and a nudge higher ahead of today's print. JPMorgan and Keefe, Bruyette & Woods both sit at Neutral/Market Perform with $44 targets, leaving the consensus mean at $45.80 against a current price of $42.31. That implies modest upside but not a ringing endorsement. Valuation tells a similar story: ACT trades at roughly 8.7x trailing earnings and just under book value (P/B ~1.0x), metrics consistent with a steady, low-growth specialty insurer rather than a re-rating candidate. The dividend score ranks in the 99th percentile, signalling that income investors have been a core constituency — but the dividend history in the data is stale and should not be assumed current. Among its closest peers, mortgage insurers NMIH and MTG are down roughly 9% on the week, with ESNT off around 6%, suggesting sector-wide pressure that ACT's modest 3.9% weekly decline has partially tracked.
Past earnings reactions have been uneven: a 9.6% one-day gain in early February 2026, a 4.1% drop in the following quarter, and a muted -0.8% move at the most recent print. Today's release will test whether ACT's mortgage insurance book is holding up against a softer housing backdrop — and whether Genworth's continued exit signals anything about the operating outlook beyond ordinary portfolio rebalancing.
See the live data behind this article on ORTEX.
Open ACT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
